The ENCCA network is composed of 34 partners spanning 11 European countries, and it includes 27 eminent paediatric oncology institutions.

ENCCA applies an integrative strategy, bringing all stakeholders together and providing them with common tools and approaches to solve current bottlenecks in testing new therapeutic strategies for rare cancers in a vulnerable age group.

ENCCA will implement new harmonised therapeutic strategies to allow biologically-targeted drugs and referral schemes to become standard practice.

In addition, advanced training courses will be developed to benefit the paediatric oncology community at large (clinicians, nurses, data specialists, psychologists and all professions involved in translational clinical research).


Integrating the paediatric oncology community through the ECRC

ENCCA will ensure the integration of a large number of European investigator-driven research networks to accelerate drug development and quality of care and cure for children and adolescents with cancer. These existing tumour groups have been incorporated into the 'European Clinical Research Council for Paediatric Oncology' (ECRC).

The ECRC will encourage information exchange, promote best practices and facilitate access to equipment and tools. This will help to ensure a more effective and efficient research for young patients with cancer.